News NICE rejects Eisai's Halaven in new breast cancer use NICE rejects drug after finding gap in clinical data
News NICE rejects Bayer and Eisai drugs in thyroid cancer Thyroid cancer drugs are available in Scotland and Wales
Views & Analysis Medical Affairs – the heart of a data-driven, patient-centri... Kirk Shepard, Eisai’s SVP of Global Medical Affairs Oncology, talks about how his profession has developed hugely in recent years, and how the new Medical Affairs Professional Society (MAPS) wi
News NICE finally recommends Eisai breast cancer drug after rethi... New trial evidence and price cut convinces NICE in reassessment.
News Nissan stays in UK - but will Japanese pharma? Japanese R&D investment could follow EMA out of UK - experts.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
